5 June 2017

ASX Code: MXC

European Medical Cannabis License Granted Under New Strategic Research Collaboration

ASX RELEASE

- Strategic research agreement signed with University of Ljubljana, who have been issued a full medical cannabis licenses for a MXC breeding and cultivation program
- The goal of the research program is to create medicinal cannabis strains tailored for specific medical indications, including epilepsy, chronic pain, as well as the side effects of oncology
- Will produce critical new genetic intellectual property for MGC Pharmaceuticals, giving it a strong competitive advantage for future production operations
- Research program aims to create medicinal cannabis strains tailored for specific medical indications, by:
    - Developing new, improved varieties of medicinal cannabis via cross breeding from MGC Pharmaceuticals' proprietary strains
    - Developing fast and efficient cannabis breeding methods
- Program to be run at the Biotechnical Faculty and led by Jana Murovec, PhD, in collaboration with Marko Flajšman, PhD, and the highly-respected Professor Borut Bohanec, PhD, head of the Centre for Plant Biotechnology and Breeding
- Builds the Company's global medical cannabis genetics and breeding research programs, with its Panax acquisition and operations in the Czech Republic and its recently announced partnership with RMIT in Australia

MGC Pharmaceuticals Ltd (ASX: **MXC** or "**the Company**") is pleased to announce that it has signed an Agreement with the Biotechnical Faculty of the University of Ljubljana (**the Faculty**) in Slovenia to commence a 3-year comprehensive botanical research program.

To facilitate the research program, the Faculty has been granted a full medical cannabis license (**License**) from the Ministry of Health of the Republic of Slovenia. The License allows the Faculty to grow and conduct botanical research with MXC in Slovenia for all strains of CBD and THC medical cannabis.

Working with Faculty, the research program will focus on:

- Developing new, improved varieties from MGC Pharmaceuticals' proprietary strains
- Developing fast and efficient cannabis breeding methods based on modern scientific approaches

The goal of the research program is to create medicinal cannabis strains tailored for specific medical indications, including epilepsy, chronic pain, as well as the side effects of oncology.

info@mgcpharma.com.au | www.mgcpharma.com.au
MGC Pharmaceuticals Ltd | Level 7, 1008 Hay Street, Perth WA 6000
PO Box 7209, Cloisters Square WA 6850
T +61 8 9389 2000 | F +61 8 9389 2099

The research program will be led by Dr Jana Murovec, PhD, Marko Flajšman, PhD, and Professor Borut Bohanec, PhD, who is the is head of the Centre for Plant Biotechnology and Breeding and at the Biotechnical Faculty. Professor Bohanec is a well-respected specialist in plant breeding and plant biotechnology and sits on the editorial boards of four international scientific journals. He is frequently invited to speak at several international scientific conferences.

Image: *University of Ljubljana researchers, Marko Flajšman, Jana Murovec and Borut Bohanec, in Biotechnical Faculty's greenhouse with industrial cannabis in the background.*

Development of Major Intellectual Property Database for MXC

The results of the research are expected to yield new genetic intellectual property relating to medicinal cannabis strains. The new varieties will be registered in the European Union. It is likely that when medicinal cannabis is legalised in European countries for medical purposes, only registered varieties of medical cannabis will be allowed to be cultivated. The new intellectual property will give the Company a strong competitive advantage for future breeding programs and its ongoing growing operations in Europe, as well as in future operations globally.

The new research builds on the Company's existing medicinal cannabis research program being conducted by Panax Pharma (MXC 80%) and license held by the Institute of Experimental Botany of the Academy of Sciences of the Czech Republic (IEB AS). The IEB AS holds a 5-year medical cannabis breeding license for its medicinal cannabis breeding and research program with the Company's subsidiary Panax Pharma. This Czech research program sits alongside the Company's planned Library of Medical Cannabis being developed in partnership with the Royal Melbourne Institute of Technology (RMIT). More broadly, the Company's global research program aims to both enhance its intellectual property development as a future core asset, and its scientific contribution to the medical cannabis industry.

Nativ Segev, Managing Director of MGC Pharmaceuticals commented:

"This new medicinal cannabis license cements our strong global botanical research credentials and has enabled us to commence an additional new genetics and cross breeding research program with the University of Ljubljana in Slovenia. The new program will help us develop additional strains of medicinal cannabis that are tailored to treat specific medical conditions, such as epilepsy, chronic pain, as well as the side effects of oncology. In addition, it builds on our existing global research credentials and operations via our Panax subsidiary in the Czech Republic, which gives us access to a 5-year medical cannabis breeding license, and our planned Library of Medical Cannabis being developed in partnership with the RMIT."

-- Ends --

For further information, please contact:

Media Enquiries
Melissa Mack
Account Director
Media and Capital Partners
+61 430 119 951
melissa.mack@mcpartners.com.au

MGC Pharmaceuticals Ltd
Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based specialist medical cannabis company with many years of technical, clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoid based pharmaceuticals products for the growing medical markets in Europe, North America and Australasia.

Follow MXC through our social media channels

About University of Ljubljana, the Biotechnical Faculty

University of Ljubljana is the oldest and largest higher education and scientific research institution in Slovenia. University with its rich tradition was founded in 1919. It has 23 faculties, which one of them is the Biotechnical Faculty. The fundamental mission of the Biotechnical Faculty of the University of Ljubljana is to perform university, higher education, professional and postgraduate education, scientific-research and expert and consulting work in the field of science about living nature (biology, microbiology) as well as agriculture, forestry and fishery (forestry, animal science, agronomy) and the related production technologies (wood science, food science, biotechnology).